Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Repatha Cholesterol Drug Cuts Risk of Cardiovascular Events in Clinical Trial

XTALKS VITALS NEWS

Along with reducing the risk of heart attacks, strokes and death in patients, the cholesterol-lowering PCSK9 inhibitor was on-par with the placebo in terms of its effect on cognitive function.

Share this!

February 6, 2017 | by Sarah Hand, M.Sc.

Initial results from Amgen’s FOURIER clinical trial show that Repatha reduces the risk of cardiovascular events in patients with heart disease. According to a press release issued by the drugmaker, more detailed results of the study will be presented at the American College of Cardiology (ACC) 66th Annual Scientific Session.

Along with reducing the risk of heart attacks, strokes and death in patients, the cholesterol-lowering PCSK9 inhibitor was on-par with the placebo in terms of its effect on cognitive function. As rare instances of neurocognitive events have occurred in some late-stage PCSK9 clinical trials, these findings help ease concerns that the drug could impair cognition.



Amgen’s previous study – the GLAGOV trial – demonstrated Repatha’s ability to reduce atherosclerosis by lowering cholesterol. The current trial did not uncover any previously-unknown safety issues associated with Repatha.

“These FOURIER results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,” said Dr. Sean E. Harper, executive vice president of Research and Development at Amgen. “Cardiovascular disease remains the number one health burden in the world, and we look forward to sharing these outcomes data with the scientific community at the ACC 66th Annual Scientific Session.”

The Phase III FOURIER trial involved approximately 27,500 patients who had previously experienced a heart attack, ischemic stroke or symptomatic peripheral artery disease. These patients were all on optimized statin therapy, and were randomly assigned to receive Repatha or a placebo injection, administered bi-weekly.

Repatha is a monoclonal antibody that inhibits the PCSK9 protein. By binding to PCSK9, Repatha prevents the protein from binding to the low-density lipoprotein (LDL) receptor (LDLR), which is responsible for removing LDL cholesterol. Repatha allows the LDLR to perform this function by removing interference from PCSK9, thereby reducing levels of LDL-C in the blood.

Cardiovascular disease is the number one cause of death globally. Approximately 11 million individuals in the US have atherosclerotic cardiovascular disease (ASCVD) and/or familial hypercholesterolemia (FH) that remains uncontrolled with statins alone.


Keywords: PCSK9, Cardiovascular Disease, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.